The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and tolerability of the combination of ATRA + arsenic trioxide (ATO) + gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): Initial report of the SWOG/Alliance/ECOG S0535 trial.
 
Jeffrey E. Lancet
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celator; Celgene; KaloBios; Seagen; Shire
Research Funding - Celgene (Inst); Pfizer (Inst)
 
Megan Othus
No Relationships to Disclose
 
Daniel J. DeAngelo
No Relationships to Disclose
 
Steven Coutre
Stock and Other Ownership Interests - Pharmacyclics (I)
Consulting or Advisory Role - Abbvie; Celgene; Genentech/Roche; Gilead Sciences; Novartis; Pharmacyclics
Research Funding - Abbvie (Inst); Celgene (Inst); Gilead Sciences (Inst); Novartis (Inst); Pharmacyclics (Inst)
Travel, Accommodations, Expenses - abbvie; Celgene; Gilead Sciences; Novartis; Pharmacyclics
 
Rami S. Komrokji
No Relationships to Disclose
 
Martin S. Tallman
No Relationships to Disclose
 
Mark Robert Litzow
No Relationships to Disclose
 
Frederick R. Appelbaum
Honoraria - Amgen; Celator; National Marrow Donor Program; Neumedicines
Consulting or Advisory Role - Amgen; Celator; National Marrow Donor Program; Neumedicines